Market cap
$2,978 Mln
Revenue (TTM)
$193 Mln
P/E Ratio
--
P/B Ratio
27.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-124 Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
77,909,504
10 Years Aggregate
CFO
$-20.47 Mln
EBITDA
$-574.61 Mln
Net Profit
$-589.59 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dicerna Pharmaceuticals Inc (DRNA)
| 73.5 | 0.6 | 90.5 | 71.5 | 53.1 | 66.0 | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Dicerna Pharmaceuticals Inc (DRNA)
| 73.5 | 0.0 | 106.1 | 18.3 | 213.5 | -75.7 | -27.9 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Dicerna Pharmaceuticals Inc (DRNA)
|
38.2 | 2,977.7 | 192.9 | -124.4 | -63.8 | -106.3 | -- | 27.7 |
| 877.7 | 54,853.1 | 6,583.9 | 2,003.3 | 14.7 | 29.9 | 39.1 | 7.5 | |
| 15.5 | 919.2 | 0.0 | -167.9 | -- | -128.7 | -- | 4.4 | |
| 25.3 | 15,514.1 | 3,900.9 | 821.0 | 23.5 | 14.4 | 19.3 | 2.7 | |
| 10.3 | 1,767.7 | 550.0 | 458.1 | -3.3 | 45.9 | 3.9 | 1.4 | |
| 3.6 | 843.3 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 14.4 | 1,857.8 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.2 | |
| 12.9 | 909.2 | 369.4 | 12.3 | 7.5 | 5 | 67.8 | 3.4 | |
| 3.2 | 583.4 | 4.0 | -198.4 | -4,917.6 | -166.3 | -- | 7.6 | |
| 18.2 | 2,042.6 | 453.3 | -178.1 | -38.4 | -25.1 | -- | 3.1 |
Shareholding Pattern
View DetailsAbout Dicerna Pharmaceuticals Inc (DRNA)
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform... for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S. Read more
-
Co-Founder, CEO, Pres & Director
Dr. Douglas M. Fambrough III
-
Co-Founder, CEO, Pres & Director
Dr. Douglas M. Fambrough III
-
Headquarters
Lexington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Dicerna Pharmaceuticals Inc (DRNA)
What is the current share price of Dicerna Pharmaceuticals Inc (DRNA) Today?
The share price of Dicerna Pharmaceuticals Inc (DRNA) is $38.22 (NASDAQ) as of 29-Dec-2021 EDT. Dicerna Pharmaceuticals Inc (DRNA) has given a return of 53.15% in the last 3 years.
What is the current PB & PE ratio of Dicerna Pharmaceuticals Inc (DRNA)?
Since, TTM earnings of Dicerna Pharmaceuticals Inc (DRNA) is negative, P/E ratio is not available.
The P/B ratio of Dicerna Pharmaceuticals Inc (DRNA) is 27.66 times as on 29-Dec-2021, a 530 premium to its peers’ median range of 4.39 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2020
|
-14.46
|
11.83
|
|
2019
|
-12.44
|
9.84
|
|
2018
|
-6.74
|
2.98
|
|
2017
|
-3.31
|
1.96
|
|
2016
|
-1.02
|
1.47
|
What is the 52 Week High and Low of Dicerna Pharmaceuticals Inc (DRNA)?
The 52-week high and low of Dicerna Pharmaceuticals Inc (DRNA) are Rs -- and Rs -- as of 22-Jun-2026.
What is the market cap of Dicerna Pharmaceuticals Inc (DRNA)?
Dicerna Pharmaceuticals Inc (DRNA) has a market capitalisation of $ 2,978 Mln as on 29-Dec-2021. As per SEBI classification, it is a company.
Should I invest in Dicerna Pharmaceuticals Inc (DRNA)?
Before investing in Dicerna Pharmaceuticals Inc (DRNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.